Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heart rate reduction after genetic ablation of L-type Cav1.3 channels induces cardioprotection against ischemia-reperfusion injury.
Delgado-Betancourt V, Chinda K, Mesirca P, Barrère C, Covinhes A, Gallot L, Vincent A, Bidaud I, Kumphune S, Nargeot J, Piot C, Wickman K, Mangoni ME, Barrère-Lemaire S. Delgado-Betancourt V, et al. Among authors: nargeot j. Front Cardiovasc Med. 2023 Aug 1;10:1134503. doi: 10.3389/fcvm.2023.1134503. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37593151 Free PMC article.
Correction: PPARβ/δ priming enhances the anti-apoptotic and therapeutic properties of mesenchymal stromal cells in myocardial ischemia-reperfusion injury.
Sarre C, Contreras-Lopez R, Nernpermpisooth N, Barrere C, Bahraoui S, Terraza C, Tejedor G, Vincent A, Luz-Crawford P, Kongpol K, Kumphune S, Piot C, Nargeot J, Jorgensen C, Djouad F, Barrere-Lemaire S. Sarre C, et al. Among authors: nargeot j. Stem Cell Res Ther. 2022 Jul 26;13(1):338. doi: 10.1186/s13287-022-03086-6. Stem Cell Res Ther. 2022. PMID: 35883123 Free PMC article. No abstract available.
PPARβ/δ priming enhances the anti-apoptotic and therapeutic properties of mesenchymal stromal cells in myocardial ischemia-reperfusion injury.
Sarre C, Contreras-Lopez R, Nernpermpisooth N, Barrere C, Bahraoui S, Terraza C, Tejedor G, Vincent A, Luz-Crawford P, Kongpol K, Kumphune S, Piot C, Nargeot J, Jorgensen C, Djouad F, Barrere-Lemaire S. Sarre C, et al. Among authors: nargeot j. Stem Cell Res Ther. 2022 Apr 23;13(1):167. doi: 10.1186/s13287-022-02840-0. Stem Cell Res Ther. 2022. PMID: 35461240 Free PMC article.
Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury.
Fernandez Rico C, Konate K, Josse E, Nargeot J, Barrère-Lemaire S, Boisguérin P. Fernandez Rico C, et al. Among authors: nargeot j. Front Cardiovasc Med. 2022 Feb 17;9:792885. doi: 10.3389/fcvm.2022.792885. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35252383 Free PMC article. Review.
PPARβ/δ Is Required for Mesenchymal Stem Cell Cardioprotective Effects Independently of Their Anti-inflammatory Properties in Myocardial Ischemia-Reperfusion Injury.
Nernpermpisooth N, Sarre C, Barrere C, Contreras R, Luz-Crawford P, Tejedor G, Vincent A, Piot C, Kumphune S, Nargeot J, Jorgensen C, Barrère-Lemaire S, Djouad F. Nernpermpisooth N, et al. Among authors: nargeot j. Front Cardiovasc Med. 2021 Sep 20;8:681002. doi: 10.3389/fcvm.2021.681002. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34616778 Free PMC article.
A novel therapeutic peptide targeting myocardial reperfusion injury.
Boisguérin P, Covinhes A, Gallot L, Barrère C, Vincent A, Busson M, Piot C, Nargeot J, Lebleu B, Barrère-Lemaire S. Boisguérin P, et al. Among authors: nargeot j. Cardiovasc Res. 2020 Mar 1;116(3):633-644. doi: 10.1093/cvr/cvz145. Cardiovasc Res. 2020. PMID: 31147690
178 results